VIDEO: Real-world data show durability of Xipere in uveitic macular edema
In this Healio Video Perspective from the Macula Society meeting, Michael A. Singer, MD, presents real-world data investigating Xipere for the treatment of uveitic macular edema.
According to Singer, ophthalmic treatments often underperform in real-world settings vs. clinical trials. In turn, Singer and colleagues looked at data from the IRIS Registry to assess Xipere (triamcinolone acetonide injectable suspension, Bausch + Lomb) in about 800 patients who were followed for 6 months.
The data showed that “patients who are given suprachoroidal triamcinolone seem to do better than the clinical trials indicate and that a vast majority of them can go 6 months or longer,” he said.
Collapse
Singer M. Durability and rescue therapy after suprachoroidal injection of triamcinolone acetonide injectable suspension for uveitic macular edema in clinical practice. Presented at: Macula Society meeting; Feb. 7-10, 2024; Palm Springs, California.
Read more about